Back to top
more

Intellia Therapeutics (NTLA)

(Real Time Quote from BATS)

$11.85 USD

11.85
1,833,547

-0.27 (-2.23%)

Updated Aug 5, 2025 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.

Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 22.92% and 103.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Zacks Equity Research

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Intellia Focuses on Pipeline Development Amid Stiff Competition

by Zacks Equity Research

Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.

Ekta Bagri headshot

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

by Ekta Bagri

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

Zacks Equity Research

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

by Zacks Equity Research

The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.

Sundeep Ganoria headshot

CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

by Sundeep Ganoria

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Zacks Equity Research

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 6.06% and 45.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

NetApp Gears Up for Q3 Earnings: Here's What You Should Know

by Zacks Equity Research

NTAP's third-quarter performance is likely to have gained from momentum in all-flash products. Muted IT spending remains a concern.

Ahan Chakraborty headshot

What's in Store for These 5 Biotech Stocks This Earnings Season?

by Ahan Chakraborty

Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

by Zacks Equity Research

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 8.62% and 4.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

by Sundeep Ganoria

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

Zacks Equity Research

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

Sundeep Ganoria headshot

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.